Latest Funding Arrangements News

Keybridge Capital has obtained a $9.3 million bridge funding facility from Active Asset Management, supported by an ASX waiver allowing the deal without prior shareholder approval. The funding aims to address urgent liquidity and solvency challenges while trading remains suspended.

Actinogen Medical has locked in up to $13.8 million in non-dilutive funding tied to its R&D tax incentives, bolstering its cash position as it advances a pivotal Alzheimer’s disease clinical trial.

Butn Limited has locked in a $10 million corporate credit facility with Mighty Partners, providing non-dilutive capital to support its expanding receivables book and operational growth.

Inventis Limited has placed its commercial furniture division into voluntary administration, triggering a default event with its lender and prompting negotiations on financial restructuring.

Mineral Commodities Ltd has extended the maturity date of its A$2.4 million convertible loan facility, tying repayment timing to the potential sale of its Skaland asset. This move provides the company with greater financial flexibility as it navigates strategic asset sales.

Alliance Nickel has strengthened its financial footing with an additional $1.2 million in unsecured loans and extended existing $4 million facilities to mid-2026, underscoring lender confidence as it advances its NiWest project.

Volt Resources has completed a scoping study for its Alabama Graphite Refinery, revealing robust project economics and a patented purification process that could reshape US graphite supply chains.

Butn Limited has raised $20 million through a $10 million equity placement and a $10 million credit facility, positioning the fintech for expanded growth in SME funding.

Peninsula Energy reports progress on its Lance Project’s Central Processing Plant and announces the termination of three sales contracts as part of a strategic reset plan, while engaging in funding discussions to support completion.

Latitude 66 Limited’s maiden reverse circulation drilling at the K6 Prospect in Finland confirms a 2.5km mineralised gold-cobalt trend, demonstrating both promising exploration potential and a new efficient drilling method for the region.

Chimeric Therapeutics has secured a $2.5 million advance against its FY25 R&D tax incentive, bolstering funding for its clinical trial pipeline and operational needs. This move complements recent capital raises and underscores the company’s strategic financial management amid its oncology-focused cell therapy development.

Titanium Sands Limited has locked in a $600,000 convertible loan facility from major shareholders to fund environmental studies and progress its Mannar Heavy Mineral Project. This funding milestone follows recent regulatory approvals and marks a critical step forward for the company.